Literature DB >> 10970835

Immunologic characterization of normal human pleural macrophages.

M Frankenberger1, B Passlick, T Hofer, M Siebeck, K L Maier, L H Ziegler-Heitbrock.   

Abstract

Human pleural macrophages (PLM) have been studied in effusions, but little is known about normal human PLM. We therefore analyzed resting human PLM recovered by lavage before lobe resection from patients with a central bronchial tumor, not involving the pleura, and from patients with pulmonary chondroma, intrapulmonary hemorrhage, and pneumothorax. Analysis of surface antigens, phagocytosis capacity, and cytokine production was done in comparison to the regular CD14(++) blood monocytes and the recently described blood monocyte subset CD14(+)CD16(+) monocytes. When defining fluorescence intensity for the various markers on CD14(++) monocytes as 100%, the PLM gave the following pattern: CD14, 45%; CD32, 200%; CD64, 72%; CD11b, 128%; CD33, 74%; CD54, 299%; and HLA-DR, 1,906%. When CD16 on the CD14(+)CD16(+) monocytes was set as 100%, the level of CD16 expression on PLM was 7.7%. Taken together, when compared to blood monocytes, PLM appear to represent a cell-type intermediate of regular CD14(++) monocytes and the CD14(+)CD16(+) subset. In functional studies, we demonstrate that PLM can perform efficient Fc-receptor-mediated phagocytosis of antibody-coated sheep red blood cells. Compared with blood monocytes, the capacity of PLM to produce tumor necrosis factor is similar, but a striking finding in PLM was the constitutive interleukin-10 messenger RNA expression that could not be substantially increased by lipopolysaccharide stimulation. This first characterization of normal, noneffusion human PLM can form the basis for a better interpretation of findings in malignant and inflammatory exudates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10970835     DOI: 10.1165/ajrcmb.23.3.4182

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  7 in total

1.  Pleural macrophages are the dominant cell population in the thoracic cavity with an inflammatory cytokine profile similar to peritoneal macrophages.

Authors:  Akihiro Shimotakahara; Joachim F Kuebler; Gertrud Vieten; Martin L Metzelder; Claus Petersen; Benno M Ure
Journal:  Pediatr Surg Int       Date:  2007-05       Impact factor: 1.827

2.  Different antigen presentation tendencies of granulocyte-macrophage colony-stimulating factor-induced bone marrow-derived macrophages and peritoneal macrophages.

Authors:  Maozhi Hu; Zhiming Pan; Yun Yang; Chuang Meng; Shizhong Geng; Meng You; Xinan Jiao
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-07-18       Impact factor: 2.416

3.  Evaluation of the phenotype pattern of macrophages isolated from malignant and non-malignant pleural effusions.

Authors:  Mariusz Kaczmarek; Agata Nowicka; Magdalena Kozłowska; Jakub Zurawski; Halina Batura-Gabryel; Jan Sikora
Journal:  Tumour Biol       Date:  2011-08-02

4.  Oxidant alterations in CD16 expression are cytoskeletal induced.

Authors:  Joseph Cuschieri; Sana Sakr; Eileen Bulger; Megan Knoll; Saman Arbabi; Ronald V Maier
Journal:  Shock       Date:  2009-12       Impact factor: 3.454

5.  Macrophages in malignant pleural effusions - alternatively activated tumor associated macrophages.

Authors:  Mariusz Kaczmarek; Jan Sikora
Journal:  Contemp Oncol (Pozn)       Date:  2012-09-29

6.  Association between inflammatory infiltrates and isolated monosomy 22/del(22q) in meningiomas.

Authors:  Patrícia Henriques Domingues; Cristina Teodósio; Álvaro Otero; Pablo Sousa; Javier Ortiz; María del Carmen García Macias; Jesús María Gonçalves; Ana Belén Nieto; María Celeste Lopes; Catarina de Oliveira; Alberto Orfao; Maria Dolores Tabernero
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

Review 7.  Role of Monocytes in Heart Failure and Atrial Fibrillation.

Authors:  Farhan Shahid; Gregory Y H Lip; Eduard Shantsila
Journal:  J Am Heart Assoc       Date:  2018-02-01       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.